These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37582500)

  • 1. A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea.
    Jo Y; Kim SB; Jung J
    J Korean Med Sci; 2023 Aug; 38(32):e250. PubMed ID: 37582500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Evaluation of Evusheld for Preexposure Prevention of COVID-19 in High-Risk Populations: Early Evidence from Thailand.
    Rattanavipapong W; Poonsiri C; Isaranuwatchai W; Iamsirithaworn S; Apakupakul J; Sonthichai C; Kitphati R; Teerawattananon Y
    Appl Health Econ Health Policy; 2023 May; 21(3):511-522. PubMed ID: 36928779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Evusheld in Immunocompromised Patients: Propensity Score-Matched Analysis.
    Najjar-Debbiny R; Gronich N; Weber G; Stein N; Saliba W
    Clin Infect Dis; 2023 Mar; 76(6):1067-1073. PubMed ID: 36310534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment.
    Focosi D; Casadevall A
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis.
    Glhoom S; Fergany A; El-Araby D; Abdelkhalek AA; Gomaa A; Zayed EO; Abd-ElGwad M
    Eur J Med Res; 2024 Jan; 29(1):27. PubMed ID: 38183123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.
    Nguyen Y; Flahault A; Chavarot N; Melenotte C; Cheminant M; Deschamps P; Carlier N; Lafont E; Thomas M; Flamarion E; Lebeaux D; Charlier C; Rachline A; Guérin C; Ratiney R; Touchard J; Péré H; Rozenberg F; Lanternier F; Arlet JB; Avouac J; Boussaud V; Guillemain R; Vignon M; Thervet E; Scemla A; Weiss L; Mouthon L;
    Clin Microbiol Infect; 2022 Dec; 28(12):1654.e1-1654.e4. PubMed ID: 35926762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tixagevimab and Cilgavimab Administration for Hemodialysis Patients at Community-Based Dialysis Centers in Singapore as Pre-Exposure Prophylaxis for SARS-CoV-2 Infection.
    Khan BA; Pagsinohin M; Lu LM; Tan P; Teo R
    Cureus; 2023 Jul; 15(7):e41297. PubMed ID: 37539406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of tixagevimab/cilgavimab in reducing SARS-CoV-2 infections, hospitalizations and mortality in inmunocompromised patients.
    Marti-Pastor M; Bou-Monterde R; Ciancotti-Oliver L; Alcover-Pons M; Amorós Cantero A; Sánchez-Lopezosa R; Montañana-Rosell N
    Med Clin (Barc); 2024 Sep; 163(6):275-280. PubMed ID: 38937218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "REAl LIfe" observational study on the effectiveness of Evusheld prophylaxis against SARS-CoV-2 omicron variants in vaccine non-responder immunocompromised patients (REALISE).
    Esposito GL; Fassio F; Girardi D; Picasso E; Meloni F; Montini S; Codullo V; Pattonieri EF; Defrancesco I; Bianchessi A; Calvi M; Seminari EM; Baldanti F; Lilleri D; Novelli V; Marena C
    Vaccine; 2024 Oct; 42(23):126208. PubMed ID: 39154513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study.
    Demel I; Skopal D; Šafránková E; Rozsívalová P; Jindra P; Šrámek J; Turková A; Vydra J; Labská K; Vedrová J; Čerňan M; Szotkowski T; Móciková H; Hynková L; Šušol O; Kováčová I; Belada D; Hájek R
    Ann Hematol; 2024 Mar; 103(3):981-992. PubMed ID: 38092996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study.
    Nassar MK; Sabry A; Elgamal M; Zeid Z; Abdellateif Abdelghany D; Tharwat S
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138212
    [No Abstract]   [Full Text] [Related]  

  • 12. Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era.
    Ntanasis-Stathopoulos I; Filippatos C; Gavriatopoulou M; Malandrakis P; Eleutherakis-Papaiakovou E; Spiliopoulou V; Syrigou RE; Theodorakakou F; Fotiou D; Migkou M; Roussou M; Kastritis E; Dimopoulos MA; Terpos E
    Diseases; 2023 Sep; 11(3):. PubMed ID: 37754319
    [No Abstract]   [Full Text] [Related]  

  • 13. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
    Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A
    J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review.
    Ustianowski A
    Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1517-1527. PubMed ID: 36217836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: A systematic review and meta-analysis.
    Soeroto AY; Yanto TA; Kurniawan A; Hariyanto TI
    Rev Med Virol; 2023 Mar; 33(2):e2420. PubMed ID: 36617704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?
    Gidari A; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Svizzeretto E; Tommasi A; Pallotto C; Schiaroli E; Francisci D
    Viruses; 2024 Feb; 16(3):. PubMed ID: 38543720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters.
    Conte WL; Golzarri-Arroyo L
    Mult Scler Relat Disord; 2022 Jul; 63():103905. PubMed ID: 35661563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Effectiveness and Safety of Tixagevimab-Cilgavimab: A Target Trial Emulation Study.
    Yan VKC; Yang Y; Wan EYF; Lai FTT; Chui CSL; Li X; Wong CKH; Hung IFN; Lau CS; Wong ICK; Chan EWY
    Drug Saf; 2024 Oct; 47(10):1025-1037. PubMed ID: 38916712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Effectiveness of Tixagevimab and Cilgavimab (Evusheld) in Patients With Hematological Malignancies.
    Ocon AJ; Ocon KE; Battaglia J; Low SK; Neupane N; Saeed H; Jamshed S; Mustafa SS
    J Hematol; 2022 Dec; 11(6):210-215. PubMed ID: 36632574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data.
    Young-Xu Y; Epstein L; Marconi VC; Davey V; Korves C; Zwain G; Smith J; Cunningham F; Bonomo RA; Ginde AA
    mBio; 2023 Aug; 14(4):e0102423. PubMed ID: 37535398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.